National Institute of Allergy and Infectious Diseases (NIAID)
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, National Institute of Allergy and Infectious Diseases (NIAID) sits in the top decile of US sponsors by registered trial count (#5 of 15,742 sponsors by registered trial count).
National Institute of Allergy and Infectious Diseases (NIAID): 2,006 sponsored US clinical trials, 155 recruiting.
National Institute of Allergy and Infectious Diseases (NIAID) sponsors 2,006 registered US clinical trials on ClinicalTrials.gov, 155 of them currently recruiting, and 1,642 completed. 177 of these trials are in Phase 3-4 (later-stage) and 1,291 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is HIV Infections, with 195 trials.
Top-decile sponsor footprint
National Institute of Allergy and Infectious Diseases (NIAID) ranks in the top decile of sponsors by registered trial count (#5 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
1,642 of 1,802 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (91.1%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
2,006 total, page 13 of 41
Evaluating the Safety and Immune Response to a Live H7N9 Influenza Virus Vaccine Followed by an Inactivated H7N9 Influenza Virus Vaccine, Given at Varying Intervals
NCT02151344
Safety and Efficacy of Mupirocin in Eradicating Colonization With S. Aureus in Critically Ill Infants
NCT01827358
Rituximab for Anti-cytokine Autoantibody-Associated Diseases
NCT01842386
Zoonotic Influenza Infections of Swine Origin at Ohio Agricultural Fairs
NCT02124096
Elite Controller and ART-treated HIV+ Statin Versus ASA Treatment Intervention Study
NCT02081638
Auranofin PK Following Oral Dose Administration
NCT02089048
ADRN Barrier/Immunoprofiling Exploratory Pilot Study
NCT02115399
Evaluating the Transition From Pediatric to Adult Care Among Adolescents With Chronic Granulomatous Disease
NCT02233036
Efficacy of Ustekinumab Followed by Abatacept for the Treatment of Psoriasis Vulgaris
NCT01999868
Safety of Sublingual dmLT for ETEC
NCT02052934
Imaging CXCR4 Expression in Subjects With Cancer Using 64 Cu-Plerixafor
NCT02069080
Study of People With HIV Infection Who Have High Viral Loads Despite Combination Antiretroviral Therapy
NCT01976715
Patients Treated for Wiskott-Aldrich Syndrome (WAS) Since 1990
NCT02064933
Evaluating the Safety and Immunogenicity of a Live Attenuated West Nile Virus Vaccine for West Nile Encephalitis in Adults 50 to 65 Years of Age
NCT02186626
Safety and Effectiveness of Low-Dose Methotrexate for Reducing Inflammation in HIV-Infected Adults on ARV Medications
NCT01949116
Safety and Pharmacokinetics of Raltegravir in HIV-1-Exposed Newborn Infants at Risk of Acquiring HIV-1 Infection
NCT01780831
BMT and High Dose Post-Transplant Cyclophosphamide for Chimerism Induction and Renal Allograft Tolerance
NCT02029638
T and B Cell Responses in Autoimmune Diseases
NCT01947036
Study of Controlled Human Malaria Infections to Evaluate Protection After Intravenous or Intramuscular Administration of PfSPZ Vaccine in Malaria-Naive Adults
NCT02015091
Anti-Influenza Hyperimmune Intravenous Immunoglobulin Pilot Study (INSIGHT 005: Flu-IVIG Pilot)
NCT02008578
The Pharmacokinetics of Extended Duration High-dose Cefixime for the Decreased Susceptibility of Neisseria Gonorrhoeae: A Phase I Pilot Study
NCT01949363
Randomized MMF Withdrawal in Systemic Lupus Erythematosus (SLE)
NCT01946880
Study of the Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-HIVMAB060-00-AB (VRC01), Administered Intravenously or Subcutaneously to Healthy Adults
NCT01993706
Study of Safety and Immunogenicity of HIV Vaccines in Healthy Volunteers
NCT01989533
Evaluating the Safety and Effectiveness of a Dengue Virus Vaccine in Healthy Adults
NCT02021968
Trichuris Suis Ova Treatment in Left-sided Ulcerative Colitis
NCT01953354
Evaluating the Safety and Immune Response to a Single Dose of a Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children
NCT01968083
Evaluating the Safety and Immune Response to a Single Dose of a Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children
NCT01852266
A Retrospective Multicenter Study to Determine 5-Year Clinical Outcomes in Subjects Previously Enrolled in the CTOT-01 Study
NCT01974999
Safety and Immunogenicity of a Live Attenuated H7N9 Influenza Virus Vaccine in Healthy Adults
NCT01995695
Study of the Safety of a Particular Herpes Vaccine in Adults With or Without Herpes Infection
NCT01915212
Evaluation of Anti-Hemagglutinin (Anti-HA) Antibodies as Protection From the Flu in Healthy People
NCT01971255
Peanut Epicutaneous Phase II Immunotherapy Clinical Trial
NCT01904604
H7N9 Mix and Match With MF59 in Healthy Adults
NCT01938742
H7N9 Mix and Match With AS03 and MF59 in Healthy Adults
NCT01942265
VRC 601: A Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC HIVMAB060-00-AB (VRC01), With Broad HIV-1 Neutralizing Activity, Administered Intravenously or Subcutaneously to HIV-Infected...
NCT01950325
Peanut Oral Immunotherapy in Children
NCT01867671
Aerosolized and Intravenous Colistin in Healthy Adults
NCT01863719
Study of the Complications Associated With Certain Stem Cell Transplants
NCT01919099
Study of Antibiotic-induced Vaginal Yeast Infections in Healthy Women
NCT01915251
Systems Biology of Influenza A (H5N1) Virus Monovalent Vaccine With and Without Adjuvant System 03 (AS03)
NCT01910519
Open-Label Phase 2 Trial of a Steroid-Free, CNI-Free, Belatacept-Based Immunosuppressive Regimen
NCT01856257
Evaluating the Safety and Immune Response to a Single Dose of a Respiratory Syncytial Virus (RSV) Vaccine in Infants and Children
NCT01893554
Evaluating the Safety and Immune Response to a Dengue Virus Vaccine in Healthy Adults
NCT01931176
Study of A Combination Pill With GS-7977 and GS-5885 for Hepatitis C in People With HIV
NCT01878799
Phase II Trial to Assess Safety and Immunogenicity of IMVAMUNE®
NCT01827371
Safety and Efficacy of Desensitization Therapy in Sensitized Participants Awaiting Heart Transplantation
NCT01769443
Vitamin D3 Treatment in Pediatric Systemic Lupus Erythematosus
NCT01709474
Therapeutic Vaccine for HIV
NCT01859325
Evaluation of Intravaginal Gel and Ovule Formulations of TOL-463
NCT01812889
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 858 |
| Phase 2 | 433 |
| Phase 3 | 123 |
| Phase 4 | 54 |
Therapeutic Areas
What is open in the National Institute of Allergy and Infectious Diseases (NIAID) pipeline
155 recruiting of 2,006 indexed (8% open); 1,642 completed (82%).
Phase mix: 177 late (III/IV) vs 1,291 early (I/II) (early-phase heavy).
Top condition: HIV Infections (195 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
National Institute of Allergy and Infectious Diseases (NIAID): open-pipeline peers nationwide
Peers matched on 2,006 registered trials and 8% open enrollment, not the therapeutic-area sidebar.
National Institute of Allergy and Infectious Diseases (NIAID) sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 2,006 trials (± recruiting share)
- Massachusetts General Hospital · 2,032 trials · 17% recruiting
- Memorial Sloan Kettering Cancer Center · 1,884 trials · 17% recruiting
- Pfizer · 1,845 trials · 6% recruiting
- Stanford University · 1,744 trials · 15% recruiting
Sponsors near 8% open enrollment (± trial volume)
- Alumis · 8% recruiting · 13 trials
- Andrei Iagaru · 8% recruiting · 13 trials
- BioXcel Therapeutics · 8% recruiting · 13 trials
- Corporal Michael J. Crescenz VA Medical Center · 8% recruiting · 13 trials
Related
What to do with this National Institute of Allergy and Infectious Diseases (NIAID) page
2,006 registered trials is a research-attention snapshot, not an endorsement of National Institute of Allergy and Infectious Diseases (NIAID) or any single study.
- 155 of National Institute of Allergy and Infectious Diseases (NIAID)'s trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- HIV Infections is the condition National Institute of Allergy and Infectious Diseases (NIAID) studies most, compare against other sponsors active in the same condition before evaluating a specific study. See HIV Infections trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. National Institute of Allergy and Infectious Diseases (NIAID) pipeline card: 2,006 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.